DOWNS CHRISTOPHER (Chief Financial Officer) purchased 181.3% of their position (66.67K shares) of CNS PHARMACEUTICALS, INC. on the open market
Open‑market purchase worth $20.0K — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 2/6/2024ACC: 0001683168-24-000706
Officer· Chief Financial Officer
Since Nov 2019
+200K
Net shares
Net buyer
$20.0K
Total acquired
1
Open market trades
1B · 0S
3
Total transactions
200K acquired
Non-Derivative Transactions1
Common stock
Direct
Shares
+66.67K
Price / share
$0.30
Trade value
$20K
% of position
181.3%
2/1/2024
36.77K→103.44K
Total
Net shares
+66.67K
Net value
$20K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common stock Direct | 2/1/2024 | P · Purchase | +66.67K | $0.30 | $20K | 181.3% | 36.77K | 103.44K |
| Total | +66.67K | $20K | ||||||
Derivative Transactions2
Series A Warrant to purchase common stock
Direct
Converts to
Common Stock
66.67K shares
Shares
+66.67K
Strike price
0.30
Held after
94.91K
Exercisable
—
2/1/2024
Series B Warrant to purchase common stock
Direct
Converts to
Common Stock
66.67K shares
Shares
+66.67K
Strike price
0.30
Held after
161.57K
Exercisable
—
2/1/2024
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Series A Warrant to purchase common stock Direct | Common Stock66.67K shares | 2/1/2024 | A · Award | +66.67K | 0.30 | — | 94.91K |
| Series B Warrant to purchase common stock Direct | Common Stock66.67K shares | 2/1/2024 | A · Award | +66.67K | 0.30 | — | 161.57K |